Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200157 | 0.75 | ALDH1A1 (0.33) | GAAALDH1A1POLBTSHRMEN1 | |
| SCHEMBL1426288 | 0.75 | — | — | |
| SCHEMBL3964643 | 0.74 | RECQL (0.33) | RECQLGAAALDH1A1NPSR1 | |
| SCHEMBL3964647 | 0.74 | GAA (0.42) | RECQLGAAALDH1A1TSHRNPSR1 | |
| SCHEMBL28716746 | 0.74 | RECQL (0.38) | RECQLGAAALDH1A1POLBNPSR1 | |
| SCHEMBL11412058 | 0.73 | GAA (0.40) | RECQLGAA | |
| SCHEMBL197543 | 0.72 | GAA (0.36) | RECQLGAAALDH1A1POLBTSHR | |
| SCHEMBL208073 | 0.72 | GAA (0.36) | RECQLGAAALDH1A1POLBTSHR | |
| SCHEMBL24214199 | 0.70 | — | — | |
| SCHEMBL28485919 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112203653-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-01-08 | — | — | CN | claimed |
| CN-112135815-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111194215-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2020-05-22 | — | — | CN | claimed |
| CN-107759460-A | A kind of method for preparing the more acid monomers of polyphenyls | 朱翠英 | 2018-03-06 | — | — | CN | claimed |
| CN-107698436-A | Method for preparing aromatic polycarboxylic acid derivative | 朱翠英 | 2018-02-16 | — | — | CN | claimed |
| CN-107698445-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | claimed |
| CN-107698437-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | claimed |
| CN-107698438-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | claimed |
| CN-101597365-B | Continuous process for producing reactive polymer | EVONIK DEGUSSA GMBH | 2013-12-18 | — | — | CN | claimed |
| CN-101497583-B | Process for the preparation of 4-amino-2,2,6,6-tetramethylpiperidine | EVONIK DEGUSSA GMBH | 2012-11-14 | — | — | CN | claimed |
| CN-101405306-B | Modified waxes, a process for their preparation, and their use | CLARIANT FINANCE BVI LTD | 2011-07-27 | — | — | CN | claimed |
| CN-101597365-A | The continuous production method of reactive polymer | EVONIK DEGUSSA GMBH (DE) | 2009-12-09 | — | — | CN | claimed |
| CN-101597366-A | The polymer composition that contains resol | EVONIK DEGUSSA GMBH (DE) | 2009-12-09 | — | — | CN | claimed |
| CN-101497583-A | Process for the preparation of 4-amino-2,2,6,6-tetramethylpiperidine | EVONIK DEGUSSA GMBH (DE) | 2009-08-05 | — | — | CN | claimed |
| CN-101405306-A | Modified waxes, a process for their preparation, and their use | CLARIANT INT LTD (VG) | 2009-04-08 | — | — | CN | claimed |
| JP-3188066-A | — | — | None | — | — | JP | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-4885347-A | UNSATURATED POLYESTER | PENNWALT CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| US-4822883-A | 2,2,6,6-TETRA SUBSTITUTED PIPERIDIN-4-YL PEROXY DERIVATIVES BECOMING CHEMICALLY BONDED TO ADDITION POLYMER | PENNWALT CORPORATION (US) | 1989-04-18 | — | — | US | disclosed |
| WO-1989001474-A1 | PEROXIDE FREE RADICAL INITIATORS CONTAINING HINDERED AMINE LIGHT STABILIZER GROUPS | PENNWALT CORPORATION (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | RECQL 1172/4885GAA 2422/4885MAPK1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.